Aller au contenu principal
Accès ouvert déclaré 2015 article

An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers

35Citations signalées — pas une note de qualité
226Institutions déclarées
25Pays d’affiliation déclarés

Résumé fourni par la source

INTRODUCTION: Individuals carrying pathogenic mutations in the BRCA1 and BRCA2 genes have a high lifetime risk of breast cancer. BRCA1 and BRCA2 are involved in DNA double-strand break repair, DNA alterations that can be caused by exposure to reactive oxygen species, a main source of which are mitochondria. Mitochondrial genome variations affect electron transport chain efficiency and reactive oxygen species production. Individuals with different mitochondrial haplogroups differ in their metabolism and sensitivity to oxidative stress. Variability in mitochondrial genetic background can alter reactive oxygen species production, leading to cancer risk. In the present study, we tested the hypothesis that mitochondrial haplogroups modify breast cancer risk in BRCA1/2 mutation carriers. METHODS: We genotyped 22,214 (11,421 affected, 10,793 unaffected) mutation carriers belonging to the Consortium of Investigators of Modifiers of BRCA1/2 for 129 mitochondrial polymorphisms using the iCOGS array. Haplogroup inference and association detection were performed using a phylogenetic approach. ALTree was applied to explore the reference mitochondrial evolutionary tree and detect subclades enriched in affected or unaffected individuals. RESULTS: We discovered that subclade T1a1 was depleted in affected BRCA2 mutation carriers compared with the rest of clade T (hazard ratio (HR) = 0.55; 95% confidence interval (CI), 0.34 to 0.88; P = 0.01). Compared with the most frequent haplogroup in the general population (that is, H and T clades), the T1a1 haplogroup has a HR of 0.62 (95% CI, 0.40 to 0.95; P = 0.03). We also identified three potential susceptibility loci, including G13708A/rs28359178, which has demonstrated an inverse association with familial breast cancer risk. CONCLUSIONS: This study illustrates how original approaches such as the phylogeny-based method we used can empower classical molecular epidemiological studies aimed at identifying association or risk modification effects.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.

Contrôle bibliographique ouvert

DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.

Titre Crossref
An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers
Date Crossref
25/04/2015
Éditeur
Springer Science and Business Media LLC
Type
journal-article

Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude et ne compte pas comme une seconde source scientifique indépendante.

Institutions déclarées

Lyon 1 UniversitéCentre National de la Recherche ScientifiqueInsermCentre de Recherche en Cancérologie de LyonLyon CollegeLaboratoire de Biométrie et Biologie EvolutiveInstitut national de recherche en sciences et technologies du numériqueLaboratoire d'Informatique de GrenobleInstitut Français de l'ÉducationUniversité Grenoble AlpesUniversity of CambridgeCancer Research UKCancer Research UK Cambridge CenterQIMR Berghofer Medical Research InstituteMRC Epidemiology UnitCentre hospitalier universitaire de QuébecCentre hospitalier de l'Université LavalUniversité LavalColumbia University Irving Medical CenterColumbia UniversityUniversity of UtahHuntsman Cancer InstituteVilnius UniversityState Research Institute Centre for Innovative MedicineLatvian Biomedical Research and Study CentreVilnius University Hospital Santariskiu KlinikosBeth Israel Deaconess Medical CenterUniversity of PretoriaCity of HopeBeckman Research InstituteCity Of Hope National Medical CenterCopenhagen University HospitalRigshospitaletUniversity of CopenhagenSpanish National Cancer Research CentreCentre for Biomedical Network Research on Rare DiseasesCentro de Investigación del CáncerHospital Clínico Universitario Lozano BlesaHoly Cross HospitalCancer Genetics (United States)Research Network (United States)John Muir Medical CenterJohn Muir HealthIFOMFondazione IRCCS Istituto Nazionale dei TumoriCentro di Riferimento OncologicoRipamontiEuropean Institute of OncologyIstituti di Ricovero e Cura a Carattere ScientificoOspedale Policlinico San MartinoAlleanza Contro il CancroLuigi Sacco HospitalUniversity of FlorenceSapienza University of RomeAristotle University of ThessalonikiPapageorgiou General HospitalNational Centre of Scientific Research "Demokritos"Dana-Farber Cancer InstituteGerman Cancer Research CenterHeidelberg UniversityDana-Farber/Harvard Cancer CenterDKFZ-ZMBH AllianceSt Michael's HospitalSt Michael’s HospitalSt Michaels HospitalWessex Regional Genetics LaboratoryRoyal Devon and Exeter HospitalUniversity of LiverpoolLiverpool Womens NHS Foundation TrustManchester Academic Health Science CentreManchester University NHS Foundation TrustUniversity of SouthamptonSouthampton General HospitalCentre for LifeNewcastle upon Tyne HospitalSheffield Children's HospitalLeeds General InfirmaryLeeds Teaching Hospitals NHS TrustLeicester Royal InfirmaryUniversity Hospitals of Leicester NHS TrustChurchill HospitalGuy's HospitalGuy's and St Thomas' NHS Foundation TrustGreat Ormond Street HospitalNational Hospital for Neurology and NeurosurgeryUniversity College LondonCambridge University Hospitals NHS Foundation TrustAddenbrooke's HospitalTrinity College DublinUniversity Hospital of WalesSt. James's HospitalWestern General HospitalQueen's University BelfastBelfast Health and Social Care TrustUniversity of UlsterBelfast City HospitalRoyal Marsden NHS Foundation TrustInstitute of Cancer ResearchWoolmanhill HospitalSt George's, University of LondonStobhill HospitalBirmingham Women's HospitalUniversity of Kansas Medical CenterGeorgetown UniversityMedStar Georgetown University HospitalGhent University HospitalTUM KlinikumTechnical University of MunichUniversity of WürzburgUniversity of CologneUniversity Hospital CologneUniversity Hospital HeidelbergLeipzig UniversityDüsseldorf University HospitalInstitute of Human GeneticsHeinrich Heine University DüsseldorfMedizinische Hochschule HannoverUniversity Hospital Carl Gustav CarusChristian-Albrechts-Universität zu KielUniversity Hospital Schleswig-HolsteinClinical Research Center KielUniversity of LübeckCharité - Universitätsmedizin BerlinUniversity Hospital MünsterTH Köln - University of Applied SciencesBreast Cancer Research FoundationUniversity Hospital UlmInstitut CurieCentre Léon BérardCentre Hospitalier Universitaire de GrenobleInstitut pour l'avancée des biosciencesHôpital René HugueninCentre Jean PerrinThe University of SydneyRoyal Prince Alfred HospitalUniversity of North Carolina at Chapel HillGynecologic Oncology GroupRoswell Park Comprehensive Cancer CenterProvidence CollegeBlackstone (United States)University of North Carolina Health CareInstituto de Investigación Sanitaria del Hospital Clínico San CarlosUniversity of HelsinkiHelsinki University HospitalWomen & Infants Hospital of Rhode IslandErasmus MCHospital Clínico San CarlosCancer ClinicRadboud University NijmegenRadboud University Medical CenterAmsterdam UMC Location University of AmsterdamErasmus MC Cancer InstituteErasmus University RotterdamThe Netherlands Cancer InstituteOncode InstituteUniversity of AmsterdamAmsterdam UMC Location Vrije Universiteit AmsterdamUniversity Medical Center GroningenNetherlands Cancer Institute-Antoni van Leeuwenhoek HospitalMaastricht UniversityLeiden University Medical CenterUniversity Medical Center UtrechtMaastricht University Medical CentreNational Institute of OncologyUniversitat Autònoma de BarcelonaVall d'Hebron Institut de RecercaInstitut d'Investigació Biomédica de BellvitgeInstitut Català d'OncologiaDuran i Reynals HospitalPomeranian Medical UniversityUniversity of IcelandNational University Hospital of IcelandHôpital Civil, StrasbourgUniversity of PaduaIstituto Oncologico VenetoUniversidade do PortoInstituto Português de Oncologia Francisco GentilMcGill UniversityMayo ClinicMayo Clinic in ArizonaNational Institutes of HealthNational Human Genome Research InstituteMemorial Sloan Kettering Cancer CenterMayo Clinic in FloridaComprehensive Cancer Center ViennaMedical University of ViennaNational Cancer InstituteTechnion – Israel Institute of TechnologyCarmel Medical CenterRappaport Family Institute for Research in the Medical SciencesClalit Health ServicesInstitute of Oncology NN PetrovUniversity of TorontoCanada Research ChairsDepartment of Health and Human ServicesMount Sinai HospitalLunenfeld-Tanenbaum Research InstituteCancer Care OntarioSt. Michael's HospitalThe Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research InstituteThe Ohio State University Wexner Medical CenterAalborg University HospitalOdense University HospitalAarhus University HospitalAzienda Ospedaliera Universitaria PisanaAalborg UniversitySheba Medical CenterRebecca Sieff HospitalKarolinska University HospitalUmeå UniversitySophiahemmet HospitalLund UniversityUppsala UniversityUniversity of ChicagoUniversity of California, San FranciscoUniversity of Southern CaliforniaUniversity of PennsylvaniaThe University of Texas MD Anderson Cancer CenterUSC Norris Comprehensive Cancer CenterPeter MacCallum Cancer CentreCedars-Sinai Medical CenterDélégation Paris 5Université Paris CitéMoffitt Cancer CenterHospices Civils de LyonCommunauté urbaine de Lyon

Une affiliation ne permet pas de déduire la nationalité d’un auteur.

Sujets associés

Mitochondrial Function and PathologyBRCA gene mutations in cancerGlutathione Transferases and Polymorphisms

BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, ROR et la Banque mondiale, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune donnée externe enregistrée en base. Sources et limites.